Tsingke Showcases AI-Driven CLDN18.2 Antibody Discovery at AIS 2026
Life science solutions provider Tsingke presented its AI-driven antibody discovery platform at the Antibody Industrial Symposium (AIS) 2026 in Montpellier, France. The company focused on the identification of antibodies targeting the CLDN18.2 antigen, relevant for cancer therapies.
Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026 in Montpellier, France, in July 2026. The company showcased its artificial intelligence-driven antibody discovery platform at the European conference focused on therapeutic antibodies and biotherapeutics.
The presentation highlighted Tsingke's approach to identifying antibodies that target the CLDN18.2 antigen. This protein is a known target in the development of antibody-based therapies for certain cancers, including gastric cancer. The use of AI aims to accelerate the identification of specific and potent antibodies.
The AIS 2026 event brings together leaders in the biopharmaceutical industry to discuss advancements in antibody development. Tsingke's participation underscores the increasing role of AI in the early stages of drug discovery, particularly within the field of oncology.
While specific details regarding the stage of development or timelines for clinical trials were not disclosed, the company emphasized the efficiency gains from its AI-powered approach. This technology has the potential to significantly shorten the preclinical phase of therapeutic antibody development.